Operating Grant: Bringing Rare Disease Gene Therapies to Clinical Trial Readiness

How to Apply: 

The specific objectives of this funding opportunity are to:

  • Increase and advance the development of gene therapies for rare disease clinical trials in Canada;
  • Generate the evidence required for first-in-human clinical trials, in part by working with Canada's biomanufacturing capacity (National Research Council of Canada) and health technology regulator (Health Canada); and,
  • Increase current and future capacity across the Canadian rare disease landscape (i.e., among researchers, knowledge users, patient(s)/caregiver(s)/family) to improve readiness of gene therapies for first-in-human clinical trials.
External Deadline: 
Wednesday, September 20, 2023
Funding Source: 
Funding Level: